8198262

7 known cases. View patent page →

Cases: 7
Active: 0; 7 closed
Filed: 2017–2022
Top venue: D. New Jersey; 4 cases

Filing activity

Cases asserting US Patent 8198262 filed per year.

Celgene Corporation v. Dr. Reddy's Laboratories, Ltd. et al.

judgment

Docket:: 2:19-cv-15343
Court:: U.S. District Court for the District of New Jersey
Filed:: 2019-07-12
Terminated:: 2022-02-23

Patents:3845770 8198262 8735428 8828427 9993467

π Celgene Corporation Δ Dr. Reddy's Laboratories, Ltd.Δ Dr. Reddy's Laboratories, Inc.

Celgene sued Dr. Reddy's in an ANDA/Hatch-Waxman action concerning pomalidomide (POMALYST®) patents, including U.S. Pat. Nos. 8,198,262; 8,735,428; 8,828,427; and 9,993,467. The narrative states that US3845770 does not appear to have been asserted in this case, despite its association with the patent-page litigation listing. Final judgment was entered on February 23, 2022.

Celgene Corp. v. MSN Laboratories Private Limited et al.

consent judgment

Docket:: 2:22-cv-01993
Court:: District of New Jersey
Filed:: 2022-04-06
Terminated:: 2022-06-15

Patents:8828427 8198262 8673939 8735428 9993467 10555939

π Celgene Corp.Δ MSN Laboratories Private Limited Δ MSN Pharmaceuticals Inc.

Hatch-Waxman ANDA litigation. Consent judgment entered June 15, 2022 (Judge Esther Salas): permanent injunction; all claims/counterclaims dismissed with prejudice. Patents-in-suit expressly included 8,828,427 plus '262, '939, '428, '467, '5939.

Celgene Corp. v. Dr. Reddy's Laboratories

Court:: District of New Jersey
Filed:: 2019-07-12

Patents:8828427 8198262 8673939 8735428 9993467

π Celgene Corp.Δ Dr. Reddy's Laboratories

Hatch-Waxman ANDA litigation filed after Dr. Reddy's ANDA (Mar. 29, 2019) and Paragraph IV notice (May 31, 2019); asserted '262, '3939, '428, '427, and '467. Outcome not confirmed in the sources reviewed.

Celgene Corporation v. Synthon Pharmaceuticals, Inc.

dismissed

Docket:: 1:18-cv-00540
Court:: U.S. District Court for the Middle District of North Carolina
Filed:: 2018-06-21
Terminated:: 2018-07-25

Patents:8198262 8673939 8735428 8828427

π Celgene Corporation Δ Synthon Pharmaceuticals, Inc.

Celgene filed a § 271 patent infringement action against Synthon in M.D.N.C. asserting US 8,198,262, 8,673,939, 8,735,428, and 8,828,427. The case was terminated July 25, 2018 by a stipulation of dismissal, described as a parallel/companion filing to the New Jersey action.

Celgene Corporation v. Hetero Labs Limited et al.

terminated

Docket:: 2:17-cv-03387
Court:: U.S. District Court for the District of New Jersey
Filed:: 2017-05-11
Terminated:: 2021-08-19

Patents:8198262

π Celgene Corporation Δ Hetero Labs Limited Δ Dr. Reddy's Laboratories, Ltd.

Celgene patent infringement action in D.N.J.; the narrative states the '262 patent is listed among the patents in this action. Sources conflict on the lead defendant/caption (Hetero vs. Dr. Reddy's), and parties reportedly include Hetero, Aurobindo, and Mylan entities.

Untitled case

unverified

Docket:: 2:17-cv-03159
Court:: U.S. District Court for the District of New Jersey

Patents:8198262

Listed on the Google Patents litigation panel for US 8,198,262 but details were not independently verified in the narrative.

Celgene Corp. v. Dr. Reddy's Laboratories, Ltd. et al.

consent judgment

Docket:: 2:19-cv-15343; 2:21-cv-02111
Court:: U.S. District Court for the District of New Jersey
Filed:: 2019-07-12
Terminated:: 2022-01-28

Patents:8673939 8198262 8735428 8828427 9993467

π Celgene Corp.Δ Dr. Reddy's Laboratories, Ltd.Δ Dr. Reddy's Laboratories, Inc.

Hatch-Waxman ANDA patent-infringement suit involving pomalidomide (ANDA No. 213234). Patents asserted included U.S. 8,198,262, 8,673,939, 8,735,428, 8,828,427, and U.S. 9,993,467. A consent judgment enjoined Dr. Reddy's from infringing the patents-in-suit until expiration and dismissed all claims, counterclaims, and defenses with prejudice.